Logo image of PASG

PASSAGE BIO INC (PASG) Stock Price, Quote, News and Overview

NASDAQ:PASG - Nasdaq - US7027121000 - Common Stock - Currency: USD

5.95  -0.84 (-12.37%)

PASG Quote, Performance and Key Statistics

PASSAGE BIO INC

NASDAQ:PASG (7/15/2025, 4:08:05 PM)

5.95

-0.84 (-12.37%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High26.6
52 Week Low5.14
Market Cap369.79M
Shares62.15M
Float56.11M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-31 2025-07-31
IPO02-28 2020-02-28


PASG short term performance overview.The bars show the price performance of PASG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

PASG long term performance overview.The bars show the price performance of PASG in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PASG is 5.95 USD. In the past month the price decreased by -21.05%. In the past year, price decreased by -62.27%.

PASSAGE BIO INC / PASG Daily stock chart

PASG Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.15 329.24B
AMGN AMGEN INC 14.09 157.29B
GILD GILEAD SCIENCES INC 14.09 135.66B
VRTX VERTEX PHARMACEUTICALS INC N/A 119.21B
REGN REGENERON PHARMACEUTICALS 12.37 59.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 40.57B
ARGX ARGENX SE - ADR 96.69 33.95B
ONC BEONE MEDICINES LTD-ADR 6.89 29.19B
BNTX BIONTECH SE-ADR N/A 26.60B
NTRA NATERA INC N/A 20.46B
INSM INSMED INC N/A 19.52B
BIIB BIOGEN INC 8.06 18.69B

About PASG

Company Profile

PASG logo image Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Company Info

PASSAGE BIO INC

One Commerce Square, 2005 Market Street, 39Th Floor

PHILADELPHIA PENNSYLVANIA 19103 US

CEO: Bruce Goldsmith

Employees: 60

PASG Company Website

PASG Investor Relations

Phone: 12678660312

PASSAGE BIO INC / PASG FAQ

What is the stock price of PASSAGE BIO INC today?

The current stock price of PASG is 5.95 USD. The price decreased by -12.37% in the last trading session.


What is the ticker symbol for PASSAGE BIO INC stock?

The exchange symbol of PASSAGE BIO INC is PASG and it is listed on the Nasdaq exchange.


On which exchange is PASG stock listed?

PASG stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PASSAGE BIO INC stock?

11 analysts have analysed PASG and the average price target is 4.42 USD. This implies a price decrease of -25.71% is expected in the next year compared to the current price of 5.95. Check the PASSAGE BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PASSAGE BIO INC worth?

PASSAGE BIO INC (PASG) has a market capitalization of 369.79M USD. This makes PASG a Small Cap stock.


How many employees does PASSAGE BIO INC have?

PASSAGE BIO INC (PASG) currently has 60 employees.


What are the support and resistance levels for PASSAGE BIO INC (PASG) stock?

PASSAGE BIO INC (PASG) has a support level at 6.51 and a resistance level at 8.67. Check the full technical report for a detailed analysis of PASG support and resistance levels.


Should I buy PASSAGE BIO INC (PASG) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PASSAGE BIO INC (PASG) stock pay dividends?

PASG does not pay a dividend.


When does PASSAGE BIO INC (PASG) report earnings?

PASSAGE BIO INC (PASG) will report earnings on 2025-07-31.


What is the Price/Earnings (PE) ratio of PASSAGE BIO INC (PASG)?

PASSAGE BIO INC (PASG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.02).


PASG Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to PASG. When comparing the yearly performance of all stocks, PASG is a bad performer in the overall market: 93.96% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PASG Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PASG. The financial health of PASG is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PASG Financial Highlights

Over the last trailing twelve months PASG reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 33.33% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -73.79%
ROE -135.87%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%16.67%
Sales Q2Q%N/A
EPS 1Y (TTM)33.33%
Revenue 1Y (TTM)N/A

PASG Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to PASG. The Buy consensus is the average rating of analysts ratings from 11 analysts.


Ownership
Inst Owners47.8%
Ins Owners0.21%
Short Float %N/A
Short Ratio4.41
Analysts
Analysts85.45
Price Target4.42 (-25.71%)
EPS Next Y15.48%
Revenue Next YearN/A